BioSpace News Archive

A new study released by the American Diabetes Association® in partnership with dQ&A, finds that growing numbers of people with diabetes have not only been forced to put off needed medical care since the outbreak of COVID-19, but that alarming numbers are struggling to manage their blood glucose levels.

The Agreement, entered into May 4, 2021, will see Ofichem provide GMP DMT product as well as the required analytical data package for use in the previously announced phase 1 human clinical trial to be conducted by the Centre for Human Drug Research.

Medical Indicators, Inc., the largest manufacturer of clinically-accurate single-use thermometers in the world, announces the launch of their blog in an effort to educate, inform, and connect with industry partners, medical personnel, and most importantly, the customers they serve.

Eloxx Pharmaceuticals, Inc. (the “Company”) (Nasdaq: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the closing of an underwritten public offering of 38,333,334 shares of common stock at a public offering price of $1.35 per share.

Gravity Diagnostics, a CAP-accredited and CLIA certified laboratory licensed in all 50 states, has announced the hire of Brian Lawrence, Ph.D. as Chief Technology Officer and General Manager of B2B and consumer products.

As clinical applications for whole slide imaging and digital pathology rapidly advance, the College of American Pathologists, in collaboration with the American Society for Clinical Pathology and the Association for Pathology Informatics, has updated the guideline “Validating Whole Slide Imaging for Diagnostic Purposes in Pathology,” published as an early online release in Archives of Pathology & Laboratory Medicine.

Micro-Tech Endoscopy recently launched the largest clip in its Lockado line of Hemostasis Clips with a 22mm jaw opening.

The Prime Meridian Group is providing Oxford BioDynamics Plc, a biotechnology company focused on the discovery and development of 3D genomic biomarkers for use within the pharmaceutical and biotechnology industry, assistance with market research related to the testing for the award-winning, proprietary technology platform, EpiSwitch™.

Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2021. First Quarter Financial Highlights: Total revenue for the first quarter of 2021 was $12.2 million, at the high end of the previously provided range of $12.0 million to $12.2 million.

Virtual KOL event to focus on the unmet medical need in relapsed/refractory EBV-positive lymphoma and the design of NAVAL-1, a global pivotal trial Event to take place on Thursday, May 20th at 2:00 PM ET